CTMX CytomX Therapeutics, Inc.: Projected Price to Earnings

Public company logo of CytomX Corp (CTMX)

CytomX Therapeutics (CTMX) develops innovative methods for combating tumors, while the firm's financial stability relies on periodic tranches from major partners, as it lacks its own profitable products. This price chart illustrates a P/E ratio of 0.00. The operating model is based on outsourcing, with third-party contractors handling drug production and testing.

CytomX Therapeutics, Inc. - CTMX Future Price to Earnings Multiple (period 07/04/2022 - 11/13/2026)

Analytical breakdowns for CytomX Corp (CTMX)

- stock quotes and analyst forecast:
Stock Price CytomX Therapeutics, Inc.|CTMX - Analyst Target Range
- company stock capitalization data:
Market Valuation CytomX Pharma|CTMX - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share CytomX Therapeutics|CTMX - Accounting Value of Company|Market Value to Book Value Ratio cytomx.com|CTMX - Total Asset Value of Company
- debt level and financial liquidity data:
Debt to Equity CytomX Therapeutics|CTMX - Long-Term Debt to Equity|Short-Term Debt to Capital CytomX Therapeutics|CTMX - Company Aggregate Debts|Debt to Book Value CytomX Pharma|CTMX - Amount of Long-Term Liabilities|Company Short-Term Debts CytomX Therapeutics|Quick Liquidity cytomx.com
- financial results and valuation multiples details:
CTMX - Company Net Income|Expected Profit CytomX Therapeutics|CTMX - Company Value to Net Income|Future Price to Earnings CytomX Therapeutics Inc|CTMX - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CytomX Pharma|CTMX - Operating income before deduction of amortization|Net earnings per share (EPS TTM) CytomX Therapeutics|CTMX - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months cytomx.com|CTMX - Earnings per share growth rate in current year|Expected earnings per share growth for next year CytomX Therapeutics
- sales volume and revenue information:
CTMX - Company Total Sales|Company Projected Revenue CytomX Therapeutics, Inc.|CTMX - Price to Sales|Price-to-Projected Revenue Ratio CytomX Pharma
Comprehensive company analysis:CytomX Therapeutics, Inc. CTMX
Signature product of CytomX Corp

The market evaluates the potential of CytomX Therapeutics (CTMX) through the lens of future cash flows. This multiple compares the current market price per share with the projected net earnings per share. By analyzing the company's forward P/E ratio, investors determine the extent of the premium paid for expected earnings. For CytomX Therapeutics (CTMX), this calculation is smoothed by Probody platform partnerships, which mitigate development risks. The asset is categorized as a high-risk biotech security.

Key competitors

Forward P/E Multiple GERN|Nanobiotix SA (NBTX) - Forward Price to Earnings Multiple|Bicycle Pharma - Projected Price to Earnings|Perspective Tx (CATX) - Projected Price to Earnings Ratio|GNLX: Projected Price to Earnings|Future Price to Earnings Multiple MOLN (molecularpartners.com)|oncolyticsbiotech.com (ONCY) - Future Price to Earnings|Price to Expected Earnings Ratio LSTA (Lisata Therapeutics, Inc.)|Future Price to Earnings Moleculin Biotech Inc|Future Price to Earnings GRTX|Forward P/E Multiple MTEM